Every material Form 8-K VERU INC. has filed with the SEC since July 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Veru said new preclinical data show its oral drug sabizabulin kept anticancer activity in daraxonrasib-resistant pancreatic cancer cell lines. The company will pursue a planned Phase 2b trial in that setting and will stop exploring sabizabulin for chronic inflammation tied to atherosclerotic cardiovascular disease. The filing contains no financial results, and the company says the work will need additional funding beyond its near-term enobosarm focus.
Preclinical study conducted in August 2026 found sabizabulin had a resistance index of 0.25 in a daraxonrasib-resistant pancreatic cancer cell line, indicating increased sensitivity
Veru plans to seek regulatory clarity from the FDA through a preIND meeting in calendar Q4 2026
Sabizabulin intellectual property protection runs until 2043, and Veru controls global development and commercialization rights
Company says it will prioritize internal cash for enobosarm, including the PLATEAU Phase 2b trial, so sabizabulin's pancreatic cancer work depends on securing additional funding
Veru reported a fiscal 2026 third-quarter net loss of $7.0 million, or $0.30 per share, versus $7.3 million, or $0.50 per share, a year earlier. Its operating loss from continuing operations rose slightly to $7.7 million from $7.5 million, as research and development expenses increased while general and administrative expenses fell. Cash, cash equivalents and restricted cash were $23.9 million at June 30, 2026, up from $15.8 million at September 30, 2025.
Q3 net loss was $7.0 million ($0.30 per share), down from $7.3 million ($0.50 per share) a year earlier.
Q3 operating loss from continuing operations was $7.7 million, up from $7.5 million; R&D rose to $4.4 million from $3.0 million, and G&A fell to $3.4 million from $5.0 million.
Nine-month net loss narrowed to $15.1 million ($0.68 per share) from $24.2 million ($1.65 per share).
Cash, cash equivalents and restricted cash were $23.9 million at June 30, 2026, versus $15.8 million at September 30, 2025.
Veru entered into a Sales Agreement with Oppenheimer & Co. and Canaccord Genuity, under which it may sell up to $21.8 million of common stock from time to time through the agents. The Company is not obligated to sell any shares, and the agents will pay a 3.0% commission on gross proceeds from each sale, so the program could dilute existing shareholders if used.
Sales Agreement dated July 2, 2026, with Oppenheimer & Co. Inc. and Canaccord Genuity LLC as sales agents
Up to $21,800,000 of common stock registered under Form S-3 (File No. 333-294911), effective April 15, 2026
Company pays a commission of 3.0% of aggregate gross proceeds from each sale
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every VERU INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →